These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 23339033)
1. Involvement of geranylgeranylation of Rho and Rac GTPases in adipogenic and RANKL expression, which was inhibited by simvastatin. Baba TT; Ohara-Nemoto Y; Miyazaki T; Nemoto TK Cell Biochem Funct; 2013 Dec; 31(8):652-9. PubMed ID: 23339033 [TBL] [Abstract][Full Text] [Related]
2. Simvastatin suppresses the differentiation of C2C12 myoblast cells via a Rac pathway. Baba TT; Nemoto TK; Miyazaki T; Oida S J Muscle Res Cell Motil; 2008; 29(2-5):127-34. PubMed ID: 18792797 [TBL] [Abstract][Full Text] [Related]
3. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation. Maeda T; Horiuchi N J Biochem; 2009 Jun; 145(6):771-81. PubMed ID: 19254925 [TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha). Woo JT; Nakagawa H; Krecic AM; Nagai K; Hamilton AD; Sebti SM; Stern PH Biochem Pharmacol; 2005 Jan; 69(1):87-95. PubMed ID: 15588717 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383 [TBL] [Abstract][Full Text] [Related]
6. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation. Lee MH; Cho YS; Han YM Stem Cells; 2007 Jul; 25(7):1654-63. PubMed ID: 17464088 [TBL] [Abstract][Full Text] [Related]
7. Geranylgeranyl pyrophosphate stimulates PPARĪ³ expression and adipogenesis through the inhibition of osteoblast differentiation. Weivoda MM; Hohl RJ Bone; 2012 Feb; 50(2):467-76. PubMed ID: 22019459 [TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Tsubaki M; Satou T; Itoh T; Imano M; Yanae M; Kato C; Takagoshi R; Komai M; Nishida S Mol Cell Endocrinol; 2012 Sep; 361(1-2):219-31. PubMed ID: 22579611 [TBL] [Abstract][Full Text] [Related]
9. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755 [TBL] [Abstract][Full Text] [Related]
10. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Massaro M; Zampolli A; Scoditti E; Carluccio MA; Storelli C; Distante A; De Caterina R Cardiovasc Res; 2010 May; 86(2):311-20. PubMed ID: 19946014 [TBL] [Abstract][Full Text] [Related]
11. Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway. Song JX; Ren JY; Chen H J Cardiovasc Pharmacol; 2011 Feb; 57(2):213-22. PubMed ID: 21052011 [TBL] [Abstract][Full Text] [Related]
12. Modulation of COX-2 expression by statins in human monocytic cells. Habib A; Shamseddeen I; Nasrallah MS; Antoun TA; Nemer G; Bertoglio J; Badreddine R; Badr KF FASEB J; 2007 Jun; 21(8):1665-74. PubMed ID: 17317725 [TBL] [Abstract][Full Text] [Related]
13. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Porter KE; Turner NA; O'Regan DJ; Balmforth AJ; Ball SG Cardiovasc Res; 2004 Mar; 61(4):745-55. PubMed ID: 14985071 [TBL] [Abstract][Full Text] [Related]
14. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376 [TBL] [Abstract][Full Text] [Related]
15. 20(S)-hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a hedgehog-dependent mechanism. Kim WK; Meliton V; Amantea CM; Hahn TJ; Parhami F J Bone Miner Res; 2007 Nov; 22(11):1711-9. PubMed ID: 17638575 [TBL] [Abstract][Full Text] [Related]
16. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Jacobson JR; Dudek SM; Birukov KG; Ye SQ; Grigoryev DN; Girgis RE; Garcia JG Am J Respir Cell Mol Biol; 2004 May; 30(5):662-70. PubMed ID: 14630613 [TBL] [Abstract][Full Text] [Related]
17. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. Yamashita M; Otsuka F; Mukai T; Otani H; Inagaki K; Miyoshi T; Goto J; Yamamura M; Makino H J Endocrinol; 2008 Mar; 196(3):601-13. PubMed ID: 18310456 [TBL] [Abstract][Full Text] [Related]
18. Resveratrol inhibits the mevalonate pathway and potentiates the antiproliferative effects of simvastatin in rat theca-interstitial cells. Wong DH; Villanueva JA; Cress AB; Sokalska A; Ortega I; Duleba AJ Fertil Steril; 2011 Nov; 96(5):1252-8. PubMed ID: 21907337 [TBL] [Abstract][Full Text] [Related]
19. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Kaji H; Kanatani M; Sugimoto T; Chihara K Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780 [TBL] [Abstract][Full Text] [Related]
20. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Schmidmaier R; Baumann P; Simsek M; Dayyani F; Emmerich B; Meinhardt G Blood; 2004 Sep; 104(6):1825-32. PubMed ID: 15161667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]